This is a preview of subscription content, log in via an institution to check access.
References
Hussein Z, Mulford DJ, Bopp BA, et al. Differences in the stereoselective pharmacokinetics of pazinaclone (DN-2327), a new anxiolytic, and its active metabolite after intravenous and oral single doses to dogs. Drug Metab Dispos 1993 Sep–Oct; 21: 805–10
Suzuki M, Uchiumi M, Murasaki M. A comparative study of the psychological effects of DN-2327, a partial benzodiazepine agonist, and alprazolam. Psychopharmacology 1995 Oct; 121 (4): 42–50
Linden M, Hadler D, Hofmann S. Randomized, double-blind, placebo-controlled trial of the efficacy and tolerability of a new isoindoline derivative (DN-2327) in generalized anxiety. Hum Psychopharm 1997 Sep–Oct; 12: 445–52
Hashimoto T, Hamada C, Wada T, et al. Comparative study on the behavioral and EEG changes induced by diazepam, buspirone and a novel anxioselective anxiolytic, DN-2327, in the cat. Neuropsychobiology 1992; 26 (1–2): 89–99
Wada T, Fukuda N. Discriminative stimulus properties of a new anxiolytic, DN-2327, in rats. Psychopharmacology 1993 Feb; 110: 280–6
Evans SM, Foltin RW, Levin FR, et al. Behavioral and subjective effects of DN-2327 (pazinaclone) and alprazolam in normal volunteers. Behav Pharmacol 1995 Mar; 6: 176–86
Dietrich B. Pharmaco EEG effects of S(+)DN-2327 enantiomer and DN-2327 racemate. Eur Neuropsychopharmacol 1996 Jun; 6 Suppl. 3: 179
Rights and permissions
About this article
Cite this article
Pazinaclone. Drugs R&D 2, 57–59 (1999). https://doi.org/10.2165/00126839-199902010-00018
Published:
Issue Date:
DOI: https://doi.org/10.2165/00126839-199902010-00018